Lapatinib
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Lapatinib |
| DrugBank ID | DB01259 |
| Brand Names (EU) | Tyverb |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.30% |
Approved Indication (EMA)
Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2): in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting; in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dermatofibrosarcoma protuberans | 99.30% | DL |
| 2 | fibroblastic neoplasm | 98.43% | DL |
| 3 | conventional fibrosarcoma | 98.36% | DL |
| 4 | kidney fibrosarcoma | 98.35% | DL |
| 5 | cysticercosis | 98.34% | DL |
| 6 | heart fibrosarcoma | 98.25% | DL |
| 7 | low grade fibromyxoid sarcoma | 98.23% | DL |
| 8 | Plasmodium falciparum malaria | 98.02% | DL |
| 9 | coenurosis | 97.46% | DL |
| 10 | HER2 positive breast carcinoma | 97.36% | DL |
| 11 | lymphangiomyoma | 97.29% | DL |
| 12 | benign PEComa | 97.29% | DL |
| 13 | uterine corpus perivascular epithelioid cell tumor | 97.26% | DL |
| 14 | autosomal recessive familial Mediterranean fever | 97.04% | DL |
| 15 | liver fibrosarcoma | 96.89% | DL |
| 16 | cutaneous undifferentiated pleomorphic sarcoma | 96.73% | DL |
| 17 | central nervous system fibrosarcoma | 96.38% | DL |
| 18 | progesterone-receptor positive breast cancer | 96.34% | DL |
| 19 | normal breast-like subtype of breast carcinoma | 96.34% | DL |
| 20 | progesterone-receptor negative breast cancer | 96.28% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.